CJC-1295 DAC is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
CJC-1295 DAC results typically emerge over a 12-16 weeks research cycle. Early changes may be noticeable within the first 1-2 weeks, with more significant effects on sustained GH elevation appearing by weeks 4-8. Results depend on dosage (1-2 mg per injection), consistency, and individual factors.
What Results Can You Expect From CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass. Results depend on dosage (1-2 mg per injection), administration frequency (once or twice weekly), and individual factors.
The following timeline is based on standard 1-2 mg per injection protocols over a 12-16 weeks cycle.
What Happens in Weeks 1-2 of CJC-1295 DAC?
During the first two weeks, CJC-1295 DAC is establishing baseline blood levels. With a half-life of 6-8 days, steady-state concentrations are typically reached within 4-5 half-lives.
Subtle changes researchers may notice: improved sustained GH elevation, better sleep quality (commonly reported across peptide protocols), and mild injection site reactions that typically resolve.
What Changes by Weeks 3-4?
By week 3-4, the biological pathways CJC-1295 DAC targets are becoming measurably activated. Binds GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and secretion. The DAC module covalently binds to endogenous albumin, extending the half-life to 6-8 days while maintaining rec.
More noticeable effects on sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis begin to emerge. This is the phase where most researchers report the first clear evidence that the compound is working.
What Results Appear at Weeks 5-8?
Weeks 5-8 represent the peak response window for most GHRH analog with extended half-life compounds. Cumulative effects of consistent once or twice weekly dosing at 1-2 mg per injection produce the most visible changes.
Key results during this phase typically include pronounced improvements in sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass. This is when before-and-after differences become most apparent.
What About Weeks 8-12 and Beyond?
For extended CJC-1295 DAC cycles (12-16 weeks), weeks 8-12 often show the most dramatic cumulative results. However, diminishing returns and receptor adaptation can occur.
Many protocols include a washout period after the cycle to restore baseline sensitivity. Synergizes with GHRP-6 or GHRP-2 for amplified GH pulse amplitude. The sustained release makes it less ideal for stacking than CJC-1295 no DAC, which preserves natural pulsatility.
How Can You Maximize CJC-1295 DAC Results?
Consistent dosing at 1-2 mg per injection once or twice weekly is the single biggest factor. Skipping doses or inconsistent timing significantly reduces outcomes.
Proper storage (reconstituted at 2-8°C), sourcing from COA-tested vendors, and supporting protocols (nutrition, sleep, training where applicable) all contribute to results.
Synergizes with GHRP-6 or GHRP-2 for amplified GH pulse amplitude. The sustained release makes it less ideal for stacking than CJC-1295 no DAC, which preserves natural pulsatility.
Calculate Your CJC-1295 DAC Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295 DAC.
Open Calculator →What Is the Realistic CJC-1295 DAC Timeline?
Expect initial effects in weeks 1-2, noticeable changes by weeks 3-4, and peak results during weeks 5-8 of a 12-16 weeks cycle. CJC-1295 DAC is not instant — consistent dosing and patience are required.
CJC-1295 DAC is not fda-approved. development discontinued post-phase ii. wada banned. available as research peptide.
Complete Guide
CJC-1295 DAC : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 DAC Dosage Guide
- CJC-1295 DAC Benefits
- CJC-1295 DAC Side Effects
- CJC-1295 DAC Stacking Guide
- CJC-1295 DAC Cycle Guide
- CJC-1295 DAC Research
Research-Grade Sourcing
If you're going to research CJC-1295 DAC, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Synthetic GHRH analog with four amino acid substitutions conjugated to a drug affinity complex that binds endogenous albumin. It is researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What is the recommended CJC-1295 DAC dosage?
Common dosages: 1-2 mg per injection administered once or twice weekly via subcutaneous injection. Cycle length: 12-16 weeks. Half-life: 6-8 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295 DAC?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
Is CJC-1295 DAC safe?
CJC-1295 DAC has shown a preliminary safety profile in research. Not FDA-approved. Development discontinued post-Phase II. WADA banned. Available as research peptide. All research should follow appropriate safety protocols.